JP2004513616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513616A5 JP2004513616A5 JP2002505816A JP2002505816A JP2004513616A5 JP 2004513616 A5 JP2004513616 A5 JP 2004513616A5 JP 2002505816 A JP2002505816 A JP 2002505816A JP 2002505816 A JP2002505816 A JP 2002505816A JP 2004513616 A5 JP2004513616 A5 JP 2004513616A5
- Authority
- JP
- Japan
- Prior art keywords
- morbillivirus
- mutation
- amino acids
- group
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21365500P | 2000-06-23 | 2000-06-23 | |
| PCT/US2001/019806 WO2002000694A2 (en) | 2000-06-23 | 2001-06-21 | Modified morbillivirus v proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513616A JP2004513616A (ja) | 2004-05-13 |
| JP2004513616A5 true JP2004513616A5 (https=) | 2008-08-07 |
Family
ID=22795965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002505816A Pending JP2004513616A (ja) | 2000-06-23 | 2001-06-21 | 改変モルビリウイルスタンパク質 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6664066B2 (https=) |
| EP (1) | EP1292615B1 (https=) |
| JP (1) | JP2004513616A (https=) |
| KR (1) | KR100885325B1 (https=) |
| CN (1) | CN1298738C (https=) |
| AT (1) | ATE343589T1 (https=) |
| AU (2) | AU2001267014B2 (https=) |
| BR (1) | BR0111827A (https=) |
| CA (1) | CA2409432C (https=) |
| CY (1) | CY1105842T1 (https=) |
| DE (1) | DE60124098T2 (https=) |
| DK (1) | DK1292615T3 (https=) |
| ES (1) | ES2273852T3 (https=) |
| IL (1) | IL153004A0 (https=) |
| MX (1) | MXPA02012256A (https=) |
| PT (1) | PT1292615E (https=) |
| WO (1) | WO2002000694A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| EP1633860A2 (en) | 2003-06-09 | 2006-03-15 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
| DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| US20090017517A1 (en) * | 2007-07-13 | 2009-01-15 | Medimmune, Llc | Preparation of Negative-Stranded RNA Viruses by Electroporation |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013107290A1 (en) * | 2012-01-20 | 2013-07-25 | The Government of the Hong Kong Special Administrative Region of the People's Republic of China | A novel paramyxovirus and uses thereof |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US11100434B2 (en) | 2014-05-06 | 2021-08-24 | Uber Technologies, Inc. | Real-time carpooling coordinating system and methods |
| US9552559B2 (en) | 2014-05-06 | 2017-01-24 | Elwha Llc | System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user |
| US10458801B2 (en) | 2014-05-06 | 2019-10-29 | Uber Technologies, Inc. | Systems and methods for travel planning that calls for at least one transportation vehicle unit |
| CN106537444A (zh) | 2014-05-06 | 2017-03-22 | 埃尔瓦有限公司 | 用于要求至少一个运输车辆单元的出行计划的系统和方法 |
| CA2955124C (en) * | 2014-07-18 | 2024-01-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0) |
| WO2016029168A1 (en) | 2014-08-21 | 2016-02-25 | Uber Technologies, Inc. | Arranging a transport service for a user based on the estimated time of arrival of the user |
| US10685416B2 (en) | 2015-12-10 | 2020-06-16 | Uber Technologies, Inc. | Suggested pickup location for ride services |
| US10731998B2 (en) | 2017-11-05 | 2020-08-04 | Uber Technologies, Inc. | Network computer system to arrange pooled transport services |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257175T1 (de) | 1994-07-18 | 2004-01-15 | Conzelmann Karl Klaus Prof Dr | Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus |
| ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| CA2265554A1 (en) * | 1996-09-27 | 1998-04-02 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales |
| BR9809456B1 (pt) | 1997-05-23 | 2011-06-28 | molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica. | |
| CA2323927A1 (en) * | 1998-03-26 | 1999-09-30 | American Cyanamid Company | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
-
2001
- 2001-06-21 AT AT01944623T patent/ATE343589T1/de not_active IP Right Cessation
- 2001-06-21 JP JP2002505816A patent/JP2004513616A/ja active Pending
- 2001-06-21 IL IL15300401A patent/IL153004A0/xx unknown
- 2001-06-21 DK DK01944623T patent/DK1292615T3/da active
- 2001-06-21 AU AU2001267014A patent/AU2001267014B2/en not_active Ceased
- 2001-06-21 PT PT01944623T patent/PT1292615E/pt unknown
- 2001-06-21 US US10/311,582 patent/US6664066B2/en not_active Expired - Fee Related
- 2001-06-21 AU AU6701401A patent/AU6701401A/xx active Pending
- 2001-06-21 WO PCT/US2001/019806 patent/WO2002000694A2/en not_active Ceased
- 2001-06-21 KR KR1020027017494A patent/KR100885325B1/ko not_active Expired - Fee Related
- 2001-06-21 EP EP01944623A patent/EP1292615B1/en not_active Expired - Lifetime
- 2001-06-21 DE DE60124098T patent/DE60124098T2/de not_active Expired - Lifetime
- 2001-06-21 MX MXPA02012256A patent/MXPA02012256A/es active IP Right Grant
- 2001-06-21 CA CA2409432A patent/CA2409432C/en not_active Expired - Fee Related
- 2001-06-21 ES ES01944623T patent/ES2273852T3/es not_active Expired - Lifetime
- 2001-06-21 BR BR0111827-7A patent/BR0111827A/pt not_active Application Discontinuation
- 2001-06-21 CN CNB018116426A patent/CN1298738C/zh not_active Expired - Fee Related
-
2006
- 2006-12-11 CY CY20061101780T patent/CY1105842T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513616A5 (https=) | ||
| CA2409432A1 (en) | Modified morbillivirus v proteins | |
| Cattaneo et al. | Biased hypermutation and other genetic changes in defective measles viruses in human brain infections | |
| Toyoda et al. | Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus | |
| Bailey et al. | Full genome sequence of peste des petits ruminants virus, a member of the Morbillivirus genus | |
| KR100525687B1 (ko) | 재조합체 센다이바이러스 | |
| Mazumder et al. | Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: transdominant negative phenotype of phosphorylation-defective P mutants | |
| JP4189035B2 (ja) | 溶解性を向上させた組換えヒトインターフェロン−β | |
| Blumberg et al. | Analysis of the Sendai virus M gene and protein | |
| CN110997922B (zh) | 使用双链多联体dna的无细胞蛋白质表达 | |
| JP2021508435A (ja) | 改変トランスアミナーゼポリペプチドおよびそれらの使用 | |
| JP7083408B2 (ja) | アミノ酸デヒドロゲナーゼ突然変異体及びその応用 | |
| JPWO2020218419A5 (https=) | ||
| CN115443288A (zh) | 一种免疫球蛋白降解酶IdeE的突变体 | |
| Leyrer et al. | Rapid and efficient recovery of Sendai virus from cDNA: factors influencing recombinant virus rescue | |
| WO2023035372A1 (zh) | 一种有限自我复制mRNA分子系统、制备方法及应用 | |
| JP2005514003A (ja) | 高いプライミング特異性を有するｄｎａの低温サイクル伸長 | |
| CA2333313A1 (en) | Novel methods for rescue of rna viruses | |
| JP2024507732A5 (https=) | ||
| JP2020535810A (ja) | 改変デカルボキシラーゼポリペプチドおよびβ−アラニンの調製におけるそれらの用途 | |
| WO2000028039A3 (en) | Identification of senv genotypes | |
| CA2289776A1 (en) | An infectious clone for human parainfluenza virus type 3 | |
| CN1294628A (zh) | 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变 | |
| JP2024509146A (ja) | コロナウイルスに対して保護するためのワクチン産生のための完全合成長鎖核酸 | |
| JP2024518548A5 (https=) |